Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

Natalia Espinola (), Constanza Silvestrini (), Carla Colaci (), Daniela Sugg (), Carlos Rojas-Roque (), Jesica Coelli () and Federico Augustovski ()
Additional contact information
Natalia Espinola: Institute for Clinical Effectiveness and Health Policy (IECS)
Constanza Silvestrini: Institute for Clinical Effectiveness and Health Policy (IECS)
Carla Colaci: Institute for Clinical Effectiveness and Health Policy (IECS)
Daniela Sugg: Sugg y Asociados Consultancy
Carlos Rojas-Roque: Institute for Clinical Effectiveness and Health Policy (IECS)
Jesica Coelli: Institute for Clinical Effectiveness and Health Policy (IECS)
Federico Augustovski: Institute for Clinical Effectiveness and Health Policy (IECS)

PharmacoEconomics - Open, 2024, vol. 8, issue 5, No 8, 727-738

Abstract: Abstract Objectives The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina. Methods A BIA model was used to estimate the cost difference between the current scenario (without olaparib) and the new scenario (incorporation of olaparib) for a third-party payer over a 5-year time horizon. The budgetary impact is estimated at the national health system level and by healthcare sectors in Argentina. Input parameters were obtained from the literature and validated by local expert opinion. Direct medical costs were obtained from both the Institute for Clinical Effectiveness and Health Policy (IECS) unit cost database and public data in Argentina. The microcosting estimation was used for key variables of the analysis. All costs are reported in US dollars (US$) as for October 2022 (1 US$ = 152.59 Argentine pesos). One-way sensitivity analyses and scenario analyses were conducted to evaluate the model robustness. Results The incorporation of olaparib, with a wholesale price per pack of US$3176, was associated with a weighted average of the budget impact per member per month (PMPM) of US$0.0191 for the national health system, being slightly higher than the estimated budgeted high impact threshold (US$0.0153). The PMPM budget impact for a 5-year average ranged between US$0.007 (public sector) and US$0.033 (private sector). The duration of treatment with olaparib was the most influential parameter in the budget impact results. Conclusions The introduction of olaparib for the treatment of metastatic castration-resistant prostate cancer has a high budget impact for Argentina's health system. These findings are informative to support policy decisions aimed to expand the current treatment landscape for prostate cancer.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00508-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00508-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00508-4

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().